Results 111 to 120 of about 30,309,938 (297)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : December 28, 2020 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : May 16, 2022

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19). These Clinical Laboratory COVID-19 Response Calls take place on

core  

Clinical laboratory COVID-19 response call : November 16, 2020 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : March 8, 2021

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : July 18, 2022

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19). These Clinical Laboratory COVID-19 Response Calls take place on

core  

Clinical laboratory COVID-19 response call : August 3, 2020 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core